Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Future Oncology (London, England)|July 29, 2024
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancerErika P Hamilton, Cynthia Ma, Michelino De Laurentiis, et al.
Blood Advances|September 20, 2021
HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteinsXiaoyu Jiang, XiaoQing Lu, Andrew J Gentles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2025
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast CancerMaxwell R Lloyd, Caroline M Weipert, Azka Ali, et al.
The Oncologist|February 3, 2016
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant GliomaAmir T Fathi, Brian V Nahed, Seth A Wander, et al.
EMBO Molecular Medicine|August 29, 2013
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responsesDiana J Azzam, Dekuang Zhao, Jun Sun, et al.
JCO Precision Oncology|January 20, 2022
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast CancerMarko Velimirovic, Dejan Juric, Andrzej Niemierko, et al.
The Oncologist|December 9, 2022
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case SeriesJamie O Brett, Lauren L Ritterhouse, Erik T Newman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast CancerRobert Wesolowski, Hope S Rugo, Jennifer M Specht, et al.
Breast Cancer Research : BCR|October 2, 2023
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast CancerJoshua Z Drago, Luigi Formisano, Dejan Juric, et al.
Pageof 8